Nathan Dowden

Nathan Dowden

Vermogen: 1 M $ op 31-07-2026

56 jaar
Commercial Services
Consumer Services
Health Technology

Profiel

Nathan J.
Dowden
is President & Chief Operating Officer at Entrada Therapeutics, Inc. since 2024, with employment at Entrada Therapeutics, Inc. starting in 2019.
Former positions include Managing Director at Huron Consulting Group, Inc. from 2014 to 2016; Managing Director at Frankel Group LLC; Senior Consultant at Ernst & Young LLP; Principal at G.D.
Searle & Co., Inc.; Analyst at CIGNA HealthCare, Inc. from 2013 to 2019; and Senior VP-Strategy & Corporate Development at Rubius Therapeutics, Inc. from 2016 to 2019.
Education includes undergraduate studies at the University of Connecticut and an MBA from The University of Chicago Booth School of Business.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
04-05-2026 198.588 ( 0,51% ) 1 M $ 31-07-2026

Actieve functies van Nathan Dowden

BedrijvenFunctieBegin
ENTRADA THERAPEUTICS, INC. President 01-01-2024

Eerdere bekende functies van Nathan Dowden

BedrijvenFunctieEinde
RUBIUS THERAPEUTICS Corporate Officer/Principal 25-07-2019
Corporate Officer/Principal 01-01-2019
HURON CONSULTING GROUP INC. Corporate Officer/Principal 01-03-2016
Frankel Group LLC
Corporate Officer/Principal -
Corporate Officer/Principal -
Ervaring van Nathan Dowden in detail bekijken

Opleiding van Nathan Dowden

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

65

Eerstegraads connecties

9

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit9

Commercial Services

Commercial Services

Process Industries

Consumer Services

Health Services

Consumer Services

Health Technology

Health Technology

Frankel Group LLC

  1. Beurs
  2. Insiders
  3. Nathan Dowden